Display options
Cite
Ehyaei S, Hedayati M, Zarif-Yeganeh M, et al. Plasma Calcitonin Levels and miRNA323 Expression in Medullary Thyroid Carcinoma Patients with or without RET Mutation. Asian Pac J Cancer Prev. 2017;18(8):2179-2184doi: 10.22034/APJCP.2017.18.8.2179.
Ehyaei, S., Hedayati, M., Zarif-Yeganeh, M., Sheikholeslami, S., Ahadi, M., & Amini, S. A. (2017). Plasma Calcitonin Levels and miRNA323 Expression in Medullary Thyroid Carcinoma Patients with or without RET Mutation. Asian Pacific journal of cancer prevention : APJCP, 18(8), 2179-2184. https://doi.org/10.22034/APJCP.2017.18.8.2179
Ehyaei, Samira, et al. "Plasma Calcitonin Levels and miRNA323 Expression in Medullary Thyroid Carcinoma Patients with or without RET Mutation." Asian Pacific journal of cancer prevention : APJCP vol. 18,8 (2017): 2179-2184. doi: https://doi.org/10.22034/APJCP.2017.18.8.2179
Ehyaei S, Hedayati M, Zarif-Yeganeh M, Sheikholeslami S, Ahadi M, Amini SA. Plasma Calcitonin Levels and miRNA323 Expression in Medullary Thyroid Carcinoma Patients with or without RET Mutation. Asian Pac J Cancer Prev. 2017 Aug 27;18(8):2179-2184. doi: 10.22034/APJCP.2017.18.8.2179. PMID: 28843253; PMCID: PMC5697478.
Copy Download .nbib Format: NLM
Share it on

Asian Pac J Cancer Prev. 2017 Aug 27;18(8):2179-2184. doi: 10.22034/APJCP.2017.18.8.2179.

Plasma Calcitonin Levels and miRNA323 Expression in Medullary Thyroid Carcinoma Patients with or without RET Mutation.

Asian Pacific journal of cancer prevention : APJCP

Samira Ehyaei, Mehdi Hedayati, Marjan Zarif-Yeganeh, Sara Sheikholeslami, Mahsa Ahadi, Sayed Asadollah Amini

Affiliations

  1. Department of clinical biochemistry, Faculty of Medical Sciences, Shahrekord University of Medical Science, Shahrekord, Iran. Email: [email protected]

PMID: 28843253 PMCID: PMC5697478 DOI: 10.22034/APJCP.2017.18.8.2179

Abstract

Background: Medullary thyroid cancer (MTC) is an endocrine tumor featuring parafollicular or C-cell differentiation, with calcitonin as a specific biomarker in MTC diagnosis. Germline mutations in the RET proto-oncogene are considered responsible for its familial occurrence and somatic mutations can cause sporadic lesions. MicroRNAs can act as oncogenes or tumor suppressors by inhibiting the expression of target genes.. The aim of this study was to investigate relationships between plasma levels of calcitonin and miRNA323 expression in MTC patients with or without RET mutation. Methods: In this cross-sectional study, MTC lesions (based on pathological confirmation) were investigated. Genomic DNA was extracted and Exons 10 and 11 of RET were genotyped using PCR-sequencing. Division was into two groups of 43 cases each with or without mutation. Plasma levels of calcitonin were determined in both. Results: miRNA323 was measured using real-time-PCR. After performing normality tests, independent T-tests and Mann Whitney tests were used for the statistical comparison of parametric and nonparametric data, respectively. Plasma levels of calcitonin were significantly higher in MTC cases without a RET mutation compared to those with a mutation. Conclusion: There was no significant difference between the two groups regarding the expression of miRNA323 so that this parameter could not be used as a bio-index germ line mutations in MTCs. However, determination of calcitonin levels in plasma might be helpful in this regard.

Creative Commons Attribution License

Keywords: Medullary thyroid carcinoma; RET proto-oncogene; Calcitonin; microRNA-323; FFPE

References

  1. Clin Cancer Res. 2011 Jul 15;17(14):4772-81 - PubMed
  2. Endocr Pract. 2006 Jan-Feb;12(1):63-102 - PubMed
  3. Cell. 1985 Sep;42(2):581-8 - PubMed
  4. Cancer. 1979 Mar;43(3):825-37 - PubMed
  5. Cancer Lett. 2009 Nov 28;285(2):116-26 - PubMed
  6. J Clin Endocrinol Metab. 1997 Oct;82(10):3378-82 - PubMed
  7. Nature. 2005 Jun 9;435(7043):828-33 - PubMed
  8. Vestn Khir Im I I Grek. 2008;167(1):52-6 - PubMed
  9. Clin Oncol (R Coll Radiol). 2010 Aug;22(6):475-85 - PubMed
  10. Br J Cancer. 2006 Mar 27;94(6):776-80 - PubMed
  11. Asian Pac J Cancer Prev. 2015;16(6):2107-17 - PubMed
  12. Science. 1995 Jan 20;267(5196):381-3 - PubMed
  13. N Engl J Med. 1970 Oct 22;283(17):890-5 - PubMed
  14. Clin Biochem. 2013 Jul;46(10-11):861-8 - PubMed
  15. J Clin Endocrinol Metab. 2008 Jun;93(6):2173-80 - PubMed
  16. Mol Cell Endocrinol. 1998 Feb;137(1):51-7 - PubMed
  17. Cancer Res. 1996 Mar 15;56(6):1241-3 - PubMed
  18. Curr Opin Cell Biol. 2009 Jun;21(3):470-9 - PubMed
  19. J Clin Endocrinol Metab. 2004 Feb;89(2):515-9 - PubMed
  20. Biochem Biophys Res Commun. 1993 Nov 15;196(3):1288-95 - PubMed
  21. N Engl J Med. 1971 Nov;285(20):1115-20 - PubMed
  22. Urol Oncol. 2010 Jan-Feb;28(1):4-13 - PubMed
  23. Surgery. 2001 Dec;130(6):1044-9 - PubMed
  24. Mutat Res. 2013 Jan-Mar;752(1):36-44 - PubMed
  25. Henry Ford Hosp Med J. 1992;40(3-4):264-7 - PubMed
  26. J Clin Endocrinol Metab. 2003 May;88(5):2070-5 - PubMed
  27. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1579-83 - PubMed
  28. Endocr J. 2016 Jul 30;63(7):627-32 - PubMed
  29. N Engl J Med. 2004 Oct 21;351(17 ):1764-71 - PubMed
  30. J Cancer Res Clin Oncol. 2016 Sep;142(9):2023-9 - PubMed
  31. Thyroid. 2012 Sep;22(9):890-6 - PubMed
  32. Biochim Biophys Acta. 2010 Apr;1805(2):209-17 - PubMed
  33. Thyroid. 2009 Jun;19(6):565-612 - PubMed
  34. Arq Bras Endocrinol Metabol. 2004 Feb;48(1):137-46 - PubMed
  35. Nat Clin Pract Endocrinol Metab. 2009 Jan;5(1):35-44 - PubMed
  36. Oncogene. 1997 Jun 26;14(25):3103-6 - PubMed
  37. J Clin Endocrinol Metab. 2008 May;93(5):1600-8 - PubMed
  38. J Clin Endocrinol Metab. 2004 Jan;89(1):163-8 - PubMed
  39. J Clin Endocrinol Metab. 2013 Aug;98(8):3149-64 - PubMed

Publication Types